Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Identification and functional characterization of arginine vasopressin receptor 1A : atypical chemokine receptor 3 heteromers in vascular smooth muscle.

Albee LJ, LaPorte HM, Gao X, Eby JM, Cheng YH, Nevins AM, Volkman BF, Gaponenko V, Majetschak M.

Open Biol. 2018 Jan;8(1). pii: 170207. doi: 10.1098/rsob.170207.

2.

Correction to: Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.

Moore T, Wagner CR, Scurti GM, Hutchens KA, Godellas C, Clark AL, Kolawole EM, Hellman LM, Singh NK, Huyke FA, Wang SY, Calabrese KM, Embree HD, Orentas R, Shirai K, Dellacecca E, Garrett-Mayer E, Li M, Eby JM, Stiff PJ, Evavold BD, Baker BM, Le Poole IC, Dropulic B, Clark JI, Nishimura MI.

Cancer Immunol Immunother. 2018 Feb;67(2):327. doi: 10.1007/s00262-017-2102-z.

PMID:
29264697
3.

Effects of cognate, non-cognate and synthetic CXCR4 and ACKR3 ligands on human lung endothelial cell barrier function.

Cheng YH, Eby JM, LaPorte HM, Volkman BF, Majetschak M.

PLoS One. 2017 Nov 10;12(11):e0187949. doi: 10.1371/journal.pone.0187949. eCollection 2017.

4.

Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.

Moore T, Wagner CR, Scurti GM, Hutchens KA, Godellas C, Clark AL, Kolawole EM, Hellman LM, Singh NK, Huyke FA, Wang SY, Calabrese KM, Embree HD, Orentas R, Shirai K, Dellacecca E, Garrett-Mayer E, Li M, Eby JM, Stiff PJ, Evavold BD, Baker BM, Le Poole IC, Dropulic B, Clark JI, Nishimura MI.

Cancer Immunol Immunother. 2018 Feb;67(2):311-325. doi: 10.1007/s00262-017-2073-0. Epub 2017 Oct 20. Erratum in: Cancer Immunol Immunother. 2017 Dec 20;:.

PMID:
29052782
5.

α1-Adrenergic Receptors Function Within Hetero-Oligomeric Complexes With Atypical Chemokine Receptor 3 and Chemokine (C-X-C motif) Receptor 4 in Vascular Smooth Muscle Cells.

Albee LJ, Eby JM, Tripathi A, LaPorte HM, Gao X, Volkman BF, Gaponenko V, Majetschak M.

J Am Heart Assoc. 2017 Aug 17;6(8). pii: e006575. doi: 10.1161/JAHA.117.006575.

6.

Functional and structural consequences of chemokine (C-X-C motif) receptor 4 activation with cognate and non-cognate agonists.

Eby JM, Abdelkarim H, Albee LJ, Tripathi A, Gao X, Volkman BF, Gaponenko V, Majetschak M.

Mol Cell Biochem. 2017 Oct;434(1-2):143-151. doi: 10.1007/s11010-017-3044-7. Epub 2017 Apr 28.

PMID:
28455789
7.

Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma.

Klarquist J, Tobin K, Farhangi Oskuei P, Henning SW, Fernandez MF, Dellacecca ER, Navarro FC, Eby JM, Chatterjee S, Mehrotra S, Clark JI, Le Poole IC.

Cancer Res. 2016 Nov 1;76(21):6230-6240. Epub 2016 Sep 12.

8.

Alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 can support immune responses toward tumors overexpressing ganglioside D3 in mice.

Eby JM, Barse L, Henning SW, Rabelink MJ, Klarquist J, Gilbert ER, Hammer AM, Fernandez MF, Yung N, Khan S, Miller HG, Kessler ER, Garrett-Mayer E, Dilling DF, Hoeben RC, Le Poole IC.

Cancer Immunol Immunother. 2017 Jan;66(1):63-75. doi: 10.1007/s00262-016-1920-8. Epub 2016 Oct 27.

PMID:
27787577
9.

Functional cloning of a gp100-reactive T-cell receptor from vitiligo patient skin.

Klarquist J, Eby JM, Henning SW, Li M, Wainwright DA, Westerhof W, Luiten RM, Nishimura MI, Le Poole IC.

Pigment Cell Melanoma Res. 2016 May;29(3):379-84. doi: 10.1111/pcmr.12458. Epub 2016 Mar 4.

PMID:
26824221
10.

Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo.

Webb KC, Tung R, Winterfield LS, Gottlieb AB, Eby JM, Henning SW, Le Poole IC.

Br J Dermatol. 2015 Sep;173(3):641-50. doi: 10.1111/bjd.14016. Epub 2015 Aug 25. Review.

11.

CCL22 to Activate Treg Migration and Suppress Depigmentation in Vitiligo.

Eby JM, Kang HK, Tully ST, Bindeman WE, Peiffer DS, Chatterjee S, Mehrotra S, Le Poole IC.

J Invest Dermatol. 2015 Jun;135(6):1574-1580. doi: 10.1038/jid.2015.26. Epub 2015 Jan 9.

12.

Targeting melanocyte and melanoma stem cells by 8-hydroxy-2-dipropylaminotetralin.

Bonchak JG, Eby JM, Willenborg KA, Chrobak D, Henning SW, Krzywiec A, Johnson SL, Le Poole IC.

Arch Biochem Biophys. 2014 Dec 1;563:71-8. doi: 10.1016/j.abb.2014.07.033. Epub 2014 Aug 14.

13.

Immune responses in a mouse model of vitiligo with spontaneous epidermal de- and repigmentation.

Eby JM, Kang HK, Klarquist J, Chatterjee S, Mosenson JA, Nishimura MI, Garrett-Mayer E, Longley BJ, Engelhard VH, Mehrotra S, Le Poole IC.

Pigment Cell Melanoma Res. 2014 Nov;27(6):1075-85. doi: 10.1111/pcmr.12284. Epub 2014 Jul 21.

14.

Enhanced bleaching treatment: opportunities for immune-assisted melanocyte suicide in vitiligo.

Webb KC, Eby JM, Hariharan V, Hernandez C, Luiten RM, Le Poole IC.

Exp Dermatol. 2014 Aug;23(8):529-33. doi: 10.1111/exd.12449. Epub 2014 Jul 10.

15.

A quantitative increase in regulatory T cells controls development of vitiligo.

Chatterjee S, Eby JM, Al-Khami AA, Soloshchenko M, Kang HK, Kaur N, Naga OS, Murali A, Nishimura MI, Caroline Le Poole I, Mehrotra S.

J Invest Dermatol. 2014 May;134(5):1285-1294. doi: 10.1038/jid.2013.540. Epub 2013 Dec 23.

16.

Preferential secretion of inducible HSP70 by vitiligo melanocytes under stress.

Mosenson JA, Flood K, Klarquist J, Eby JM, Koshoffer A, Boissy RE, Overbeck A, Tung RC, Le Poole IC.

Pigment Cell Melanoma Res. 2014 Mar;27(2):209-20. doi: 10.1111/pcmr.12208. Epub 2014 Jan 13.

17.

A central role for inducible heat-shock protein 70 in autoimmune vitiligo.

Mosenson JA, Eby JM, Hernandez C, Le Poole IC.

Exp Dermatol. 2013 Sep;22(9):566-9. doi: 10.1111/exd.12183. Epub 2013 Jun 20. Review.

18.

Positioning ganglioside D3 as an immunotherapeutic target in lymphangioleiomyomatosis.

Gilbert ER, Eby JM, Hammer AM, Klarquist J, Christensen DG, Barfuss AJ, Boissy RE, Picken MM, Love RB, Dilling DF, Le Poole IC.

Am J Pathol. 2013 Jul;183(1):226-34. doi: 10.1016/j.ajpath.2013.04.002. Epub 2013 May 10. Erratum in: Am J Pathol. 2013 Nov;183(5):1698.

PMID:
23665200
19.

Mutant HSP70 reverses autoimmune depigmentation in vitiligo.

Mosenson JA, Zloza A, Nieland JD, Garrett-Mayer E, Eby JM, Huelsmann EJ, Kumar P, Denman CJ, Lacek AT, Kohlhapp FJ, Alamiri A, Hughes T, Bines SD, Kaufman HL, Overbeck A, Mehrotra S, Hernandez C, Nishimura MI, Guevara-Patino JA, Le Poole IC.

Sci Transl Med. 2013 Feb 27;5(174):174ra28. doi: 10.1126/scitranslmed.3005127.

20.

A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice.

Mehrotra S, Al-Khami AA, Klarquist J, Husain S, Naga O, Eby JM, Murali AK, Lyons GE, Li M, Spivey ND, Norell H, Martins da Palma T, Onicescu G, Diaz-Montero CM, Garrett-Mayer E, Cole DJ, Le Poole IC, Nishimura MI.

J Immunol. 2012 Aug 15;189(4):1627-38. doi: 10.4049/jimmunol.1103271. Epub 2012 Jul 13.

21.

A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options.

Dilling DF, Gilbert ER, Picken MM, Eby JM, Love RB, Le Poole IC.

Am J Respir Cell Mol Biol. 2012 Jan;46(1):1-5. doi: 10.1165/rcmb.2011-0215TR. Review.

PMID:
21940815

Supplemental Content

Support Center